The original assessment, according to Prof Harmer, was highly critical of the lack of detail on secondary care but when told by Betsi Cadwaladr's chief executive that those proposals would be drawn up at a future date he said the forum had decided to redraft its evaluation accordingly.
The two companies filed a New Drug Application on Jan. 9, 2009 and learned in November that the agency extended the review date of Horizant to Feb. 9 to perform a risk evaluation and mitigation plan for the drug.